Gainers XTL Biopharmaceuticals (NASDAQ:XTLB) shares rose 17.74% to $3.65 during Thursday's after-market session. The market value of their outstanding shares is at $19.2 million.
November 24, 5:32 PM
November 1, 10:33 AM
Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that clinical and preclinical data from its HBV
Antios Therapeutics And Assembly Biosciences Announce Clinical Collaboration Agreement To Evaluate The Combination Of ATI-2173 And Vebicorvir In Patients With Chronic Hepatitis B Virus Infection
October 19, 7:34 AM
Antios Therapeutics, Inc. and Assembly Biosciences, Inc. (NASDAQ:ASMB) today announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination treatment in patients with
HC Wainwright & Co. Initiates Coverage On Assembly Biosciences with Neutral Rating, Announces Price Target of $3.5
September 13, 6:43 AM
HC Wainwright & Co. analyst Ed Arce initiates coverage on Assembly Biosciences (NASDAQ:ASMB) with a Neutral rating and announces Price Target of $3.5.
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
September 3, 7:31 AM
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2)
September 2, 3:18 PM
Toward the end of trading Thursday, the Dow traded up 0.25% to 35,402.54 while the NASDAQ rose 0.05% to 15,316.38. The S&P also rose, gaining 0.13% to 4,530.11.